{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:41Z","timestamp":1793915681186,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jns.2025.123652","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:14:10Z","timestamp":1754925250000},"page":"123652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis"],"prefix":"10.1016","volume":"477","author":[{"given":"Neelam","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Gordon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jefferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharun Balaji","family":"Suthagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit R.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Narayanaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.jns.2025.123652_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2025.123652_bb0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2025.123652_bb0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","article-title":"Alternate-day prednisone: preliminary report of a double-blind controlled study","volume":"274","author":"Howard","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"7","key":"10.1016\/j.jns.2025.123652_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2025.123652_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mus.28111","article-title":"Would glucocorticoids be approved for clinical use if discovered today?","volume":"70","author":"Habib","year":"2024","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jns.2025.123652_bb0055","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2025.123652_bb0065","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med. Sci. Monit."},{"issue":"9","key":"10.1016\/j.jns.2025.123652_bb0070","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/13696998.2018.1474750","article-title":"Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population","volume":"21","author":"Rice","year":"2018","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi","year":"2022","journal-title":"J. Pharm. Technol."},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0080","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jval.2024.03.250","article-title":"CO163 impact of glucocorticoid use on mortality in adults with chronic diseases: a systematic literature review","volume":"27","author":"Rao","year":"2024","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jns.2025.123652_bb0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2025.123652_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0095","first-page":"7","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome: an overview","volume":"76","author":"Murai","year":"2024","journal-title":"Brain Nerve"},{"issue":"2","key":"10.1016\/j.jns.2025.123652_bb0100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3949\/ccjm.90a.22022","article-title":"What are the treatment options for myasthenia gravis if first-line agents fail?","volume":"90","author":"Zust","year":"2023","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.jns.2025.123652_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of oral steroid therapy for myasthenia gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2025.123652_bb0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jns.2025.123652_bb0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.jns.2025.123652_bb0120","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/14656566.2022.2122710","article-title":"What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?","volume":"23","author":"Vanoli","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2025.123652_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2025.123652_bb0140","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2025.123652_bb0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.jns.2025.123652_bb0150","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2025.123652_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2025.123652_bb0160","author":"European Medicines Agency"},{"issue":"3","key":"10.1016\/j.jns.2025.123652_bb0165","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1212\/CPJ.0000000000200276","article-title":"Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan","volume":"14","author":"Suzuki","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jns.2025.123652_bb0170","author":"argenx"},{"key":"10.1016\/j.jns.2025.123652_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241311127","article-title":"Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study","volume":"18","author":"Zhu","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2025.123652_bb0180","author":"Therapeutic Goods Administration"},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events","author":"Singer","year":"2023","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jns.2025.123652_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2025.123652_bb0195","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251319656","article-title":"Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes","volume":"18","author":"Jin","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jns.2025.123652_bb0200","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.28334","article-title":"Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single center","volume":"71","author":"Silvestri","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2025.123652_bb0205","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","author":"Fuchs","year":"2024","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.123652_bb0210","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2025.123652_bb0215","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0220","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/acr2.11550","article-title":"Clinical and economic burden in patients with systemic lupus erythematosus during the first year after initiating oral corticosteroids: a retrospective US database study","volume":"5","author":"DerSarkissian","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.jns.2025.123652_bb0225","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0230","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2025.123652_bb0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population","volume":"45","author":"Guptill","year":"2012","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jns.2025.123652_bb0245","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","author":"Hoes","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jns.2025.123652_bb0250","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2025.123652_bb0255","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2025.123652_bb0260","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2025.123652_bb0265","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","article-title":"Recommendations for the management of myasthenia gravis in Belgium","volume":"124","author":"De Bleecker","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2025.123652_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2025.123652_bb0275","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","article-title":"Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial","volume":"78","author":"Sharshar","year":"2021","journal-title":"JAMA Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:32:24Z","timestamp":1779769944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25002722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":54,"alternative-id":["S0022510X25002722"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123652","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123652"}}